Ileal FGF15 contributes to fibrosis‐associated hepatocellular carcinoma development
Open Access
- 23 October 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 136 (10), 2469-2475
- https://doi.org/10.1002/ijc.29287
Abstract
Fibroblast growth factor 15 (FGF15), FGF19 in humans, is a gut‐derived hormone and a key regulator of bile acids and carbohydrate metabolism. FGF15 also participates in liver regeneration after partial hepatectomy inducing hepatocellular proliferation. FGF19 is overexpressed in a significant proportion of human hepatocellular carcinomas (HCC), and activation of its receptor FGFR4 promotes HCC cell growth. Here we addressed for the first time the role of endogenous Fgf15 in hepatocarcinogenesis. Fgf15+/+ and Fgf15−/− mice were subjected to a clinically relevant model of liver inflammation and fibrosis‐associated carcinogenesis. Fgf15−/− mice showed less and smaller tumors, and histological neoplastic lesions were also smaller than in Fgf15+/+ animals. Importantly, ileal Fgf15 mRNA expression was enhanced in mice undergoing carcinogenesis, but at variance with human HCC it was not detected in liver or HCC tissues, while circulating FGF15 protein was clearly upregulated. Hepatocellular proliferation was also reduced in Fgf15−/− mice, which also expressed lower levels of the HCC marker alpha‐fetoprotein (AFP). Interestingly, lack of FGF15 resulted in attenuated fibrogenesis. However, in vitro experiments showed that liver fibrogenic stellate cells were not direct targets for FGF15/FGF19. Conversely we demonstrate that FGF15/FGF19 induces the expression of the pro‐fibrogenic and pro‐tumorigenic connective tissue growth factor (CTGF) in hepatocytes. These findings suggest the existence of an FGF15‐triggered CTGF‐mediated paracrine action on stellate cells, and an amplification mechanism for the hepatocarcinogenic effects of FGF15 via CTGF production. In summary, our observations indicate that ileal FGF15 may contribute to HCC development in a context of chronic liver injury and fibrosis.Keywords
Funding Information
- FIS ISCIII. Spanish Ministry of Health (PI10/02642, PI10/00038, PI13/00385, PI13/00359, PI13/00374)
This publication has 24 references indexed in Scilit:
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular CarcinomaGastroenterology, 2013
- Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in miceGut, 2013
- Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse ModelsPLOS ONE, 2012
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinomaBMC Cancer, 2012
- FGF19 and CancerAdvances in experimental medicine and biology, 2012
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic ScreeningCancer Cell, 2011
- Roles of FGF19 in Liver MetabolismCold Spring Harbor Symposia on Quantitative Biology, 2011
- Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic interventionJournal of Hepatology, 2008
- Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma modelsOncogene, 2007
- A Mouse Model of Hepatocellular Carcinoma: Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic MiceThe American Journal of Pathology, 2002